Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer: An update from INQAT round III

A. Paradiso, E. Marubini, Paolo Verderio, M. E. Cortese, S. Pizzamiglio, F. De Paola, R. Silvestrini, G. Simone, I. Sarotto, M. L. Carcangiu, S. Menard, E. Tagliabue, M. Mottolese, M. Benevolo, M. Bisceglia, E. Giardina, E. Maiorano, A. Napoli, P. Querzoli, I. NenciM. Pedriali, R. Rinaldi, S. Bianchi, V. Vezzosi, P. Collecchi, G. Bevilacqua, R. Colombari, A. Caneva, P. Gasparin, V. Rucca, F. P. Morigi, A. Dubini, M. Gaudio, L. Medri, F. Padovani, L. Saragoni, A. Volpi, A. M. Granato, E. Marinaro, S. Folicaldi, D. Ghidoni, S. Cortecchia, S. Veronese, C. Galli, M. Gambacorta, M. Stella, A. Rizzo, R. Nizzoli, C. Bozzetti, A. M. Guazzi, N. Naldi, A. Sidoni, E. Bucciarelli, L. Ludovini, L. Pistola, L. Bernardi, G. Ghisolfi, C. Pecchioni, A. Sapino, G. Bussolati, M. Barbareschi, P. Dalla Palma, E. Leonardi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The clinical interest in HER-2/neu is related to trastuzumab, a drug used to treat patients with invasive breast carcinoma overexpressing the HER-2/neu protein. It is very important to correctly identify those patients who may benefit from trastuzumab by accurate assessment of the HER-2/neu status. Of the various methods available, the Dako Herceptest for immunohistochemical assay is considered the most reliable to reach this goal. The aim of this study was to investigate within a group of Italian laboratories the reproducibility of the results of HER-2/neu assessment by means of the Dako scoring system on slides stained with the Herceptest kit. This study was also conceived as the continuation of one of our previous studies, which was similar in its aims but different in the classification criteria adopted. Our results show that, whereas the intra-observer reproducibility was generally satisfactory, the interobserver reproducibility was not. Moreover, our findings confirm that the two extreme classes (0 and 3+) are more easy to identify than the other two and that the Herceptest does not allow to discriminate optimally between scoring classes 2+ and 3+. These findings are relevant in clinical practice where the treatment choice is based on categories defined by this assay, suggesting the need of adopting educational programs and/or new reference materials to improve the assay performance.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalInternational Journal of Biological Markers
Volume20
Issue number3
Publication statusPublished - Jul 2005

Fingerprint

Assays
Breast Neoplasms
Reproducibility of Results
Pharmaceutical Preparations
Proteins
Trastuzumab
Therapeutics

Keywords

  • Breast cancer
  • Herceptest
  • Immunohistochemical HER-2/neu assessment
  • Intra/Interoberver reproducibility
  • Quality control

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer : An update from INQAT round III. / Paradiso, A.; Marubini, E.; Verderio, Paolo; Cortese, M. E.; Pizzamiglio, S.; De Paola, F.; Silvestrini, R.; Simone, G.; Sarotto, I.; Carcangiu, M. L.; Menard, S.; Tagliabue, E.; Mottolese, M.; Benevolo, M.; Bisceglia, M.; Giardina, E.; Maiorano, E.; Napoli, A.; Querzoli, P.; Nenci, I.; Pedriali, M.; Rinaldi, R.; Bianchi, S.; Vezzosi, V.; Collecchi, P.; Bevilacqua, G.; Colombari, R.; Caneva, A.; Gasparin, P.; Rucca, V.; Morigi, F. P.; Dubini, A.; Gaudio, M.; Medri, L.; Padovani, F.; Saragoni, L.; Volpi, A.; Granato, A. M.; Marinaro, E.; Folicaldi, S.; Ghidoni, D.; Cortecchia, S.; Veronese, S.; Galli, C.; Gambacorta, M.; Stella, M.; Rizzo, A.; Nizzoli, R.; Bozzetti, C.; Guazzi, A. M.; Naldi, N.; Sidoni, A.; Bucciarelli, E.; Ludovini, L.; Pistola, L.; Bernardi, L.; Ghisolfi, G.; Pecchioni, C.; Sapino, A.; Bussolati, G.; Barbareschi, M.; Dalla Palma, P.; Leonardi, E.

In: International Journal of Biological Markers, Vol. 20, No. 3, 07.2005, p. 189-194.

Research output: Contribution to journalArticle

Paradiso, A, Marubini, E, Verderio, P, Cortese, ME, Pizzamiglio, S, De Paola, F, Silvestrini, R, Simone, G, Sarotto, I, Carcangiu, ML, Menard, S, Tagliabue, E, Mottolese, M, Benevolo, M, Bisceglia, M, Giardina, E, Maiorano, E, Napoli, A, Querzoli, P, Nenci, I, Pedriali, M, Rinaldi, R, Bianchi, S, Vezzosi, V, Collecchi, P, Bevilacqua, G, Colombari, R, Caneva, A, Gasparin, P, Rucca, V, Morigi, FP, Dubini, A, Gaudio, M, Medri, L, Padovani, F, Saragoni, L, Volpi, A, Granato, AM, Marinaro, E, Folicaldi, S, Ghidoni, D, Cortecchia, S, Veronese, S, Galli, C, Gambacorta, M, Stella, M, Rizzo, A, Nizzoli, R, Bozzetti, C, Guazzi, AM, Naldi, N, Sidoni, A, Bucciarelli, E, Ludovini, L, Pistola, L, Bernardi, L, Ghisolfi, G, Pecchioni, C, Sapino, A, Bussolati, G, Barbareschi, M, Dalla Palma, P & Leonardi, E 2005, 'Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer: An update from INQAT round III', International Journal of Biological Markers, vol. 20, no. 3, pp. 189-194.
Paradiso, A. ; Marubini, E. ; Verderio, Paolo ; Cortese, M. E. ; Pizzamiglio, S. ; De Paola, F. ; Silvestrini, R. ; Simone, G. ; Sarotto, I. ; Carcangiu, M. L. ; Menard, S. ; Tagliabue, E. ; Mottolese, M. ; Benevolo, M. ; Bisceglia, M. ; Giardina, E. ; Maiorano, E. ; Napoli, A. ; Querzoli, P. ; Nenci, I. ; Pedriali, M. ; Rinaldi, R. ; Bianchi, S. ; Vezzosi, V. ; Collecchi, P. ; Bevilacqua, G. ; Colombari, R. ; Caneva, A. ; Gasparin, P. ; Rucca, V. ; Morigi, F. P. ; Dubini, A. ; Gaudio, M. ; Medri, L. ; Padovani, F. ; Saragoni, L. ; Volpi, A. ; Granato, A. M. ; Marinaro, E. ; Folicaldi, S. ; Ghidoni, D. ; Cortecchia, S. ; Veronese, S. ; Galli, C. ; Gambacorta, M. ; Stella, M. ; Rizzo, A. ; Nizzoli, R. ; Bozzetti, C. ; Guazzi, A. M. ; Naldi, N. ; Sidoni, A. ; Bucciarelli, E. ; Ludovini, L. ; Pistola, L. ; Bernardi, L. ; Ghisolfi, G. ; Pecchioni, C. ; Sapino, A. ; Bussolati, G. ; Barbareschi, M. ; Dalla Palma, P. ; Leonardi, E. / Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer : An update from INQAT round III. In: International Journal of Biological Markers. 2005 ; Vol. 20, No. 3. pp. 189-194.
@article{9329f75f9c474b538ac69fd1d4d2d196,
title = "Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer: An update from INQAT round III",
abstract = "The clinical interest in HER-2/neu is related to trastuzumab, a drug used to treat patients with invasive breast carcinoma overexpressing the HER-2/neu protein. It is very important to correctly identify those patients who may benefit from trastuzumab by accurate assessment of the HER-2/neu status. Of the various methods available, the Dako Herceptest for immunohistochemical assay is considered the most reliable to reach this goal. The aim of this study was to investigate within a group of Italian laboratories the reproducibility of the results of HER-2/neu assessment by means of the Dako scoring system on slides stained with the Herceptest kit. This study was also conceived as the continuation of one of our previous studies, which was similar in its aims but different in the classification criteria adopted. Our results show that, whereas the intra-observer reproducibility was generally satisfactory, the interobserver reproducibility was not. Moreover, our findings confirm that the two extreme classes (0 and 3+) are more easy to identify than the other two and that the Herceptest does not allow to discriminate optimally between scoring classes 2+ and 3+. These findings are relevant in clinical practice where the treatment choice is based on categories defined by this assay, suggesting the need of adopting educational programs and/or new reference materials to improve the assay performance.",
keywords = "Breast cancer, Herceptest, Immunohistochemical HER-2/neu assessment, Intra/Interoberver reproducibility, Quality control",
author = "A. Paradiso and E. Marubini and Paolo Verderio and Cortese, {M. E.} and S. Pizzamiglio and {De Paola}, F. and R. Silvestrini and G. Simone and I. Sarotto and Carcangiu, {M. L.} and S. Menard and E. Tagliabue and M. Mottolese and M. Benevolo and M. Bisceglia and E. Giardina and E. Maiorano and A. Napoli and P. Querzoli and I. Nenci and M. Pedriali and R. Rinaldi and S. Bianchi and V. Vezzosi and P. Collecchi and G. Bevilacqua and R. Colombari and A. Caneva and P. Gasparin and V. Rucca and Morigi, {F. P.} and A. Dubini and M. Gaudio and L. Medri and F. Padovani and L. Saragoni and A. Volpi and Granato, {A. M.} and E. Marinaro and S. Folicaldi and D. Ghidoni and S. Cortecchia and S. Veronese and C. Galli and M. Gambacorta and M. Stella and A. Rizzo and R. Nizzoli and C. Bozzetti and Guazzi, {A. M.} and N. Naldi and A. Sidoni and E. Bucciarelli and L. Ludovini and L. Pistola and L. Bernardi and G. Ghisolfi and C. Pecchioni and A. Sapino and G. Bussolati and M. Barbareschi and {Dalla Palma}, P. and E. Leonardi",
year = "2005",
month = "7",
language = "English",
volume = "20",
pages = "189--194",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "3",

}

TY - JOUR

T1 - Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer

T2 - An update from INQAT round III

AU - Paradiso, A.

AU - Marubini, E.

AU - Verderio, Paolo

AU - Cortese, M. E.

AU - Pizzamiglio, S.

AU - De Paola, F.

AU - Silvestrini, R.

AU - Simone, G.

AU - Sarotto, I.

AU - Carcangiu, M. L.

AU - Menard, S.

AU - Tagliabue, E.

AU - Mottolese, M.

AU - Benevolo, M.

AU - Bisceglia, M.

AU - Giardina, E.

AU - Maiorano, E.

AU - Napoli, A.

AU - Querzoli, P.

AU - Nenci, I.

AU - Pedriali, M.

AU - Rinaldi, R.

AU - Bianchi, S.

AU - Vezzosi, V.

AU - Collecchi, P.

AU - Bevilacqua, G.

AU - Colombari, R.

AU - Caneva, A.

AU - Gasparin, P.

AU - Rucca, V.

AU - Morigi, F. P.

AU - Dubini, A.

AU - Gaudio, M.

AU - Medri, L.

AU - Padovani, F.

AU - Saragoni, L.

AU - Volpi, A.

AU - Granato, A. M.

AU - Marinaro, E.

AU - Folicaldi, S.

AU - Ghidoni, D.

AU - Cortecchia, S.

AU - Veronese, S.

AU - Galli, C.

AU - Gambacorta, M.

AU - Stella, M.

AU - Rizzo, A.

AU - Nizzoli, R.

AU - Bozzetti, C.

AU - Guazzi, A. M.

AU - Naldi, N.

AU - Sidoni, A.

AU - Bucciarelli, E.

AU - Ludovini, L.

AU - Pistola, L.

AU - Bernardi, L.

AU - Ghisolfi, G.

AU - Pecchioni, C.

AU - Sapino, A.

AU - Bussolati, G.

AU - Barbareschi, M.

AU - Dalla Palma, P.

AU - Leonardi, E.

PY - 2005/7

Y1 - 2005/7

N2 - The clinical interest in HER-2/neu is related to trastuzumab, a drug used to treat patients with invasive breast carcinoma overexpressing the HER-2/neu protein. It is very important to correctly identify those patients who may benefit from trastuzumab by accurate assessment of the HER-2/neu status. Of the various methods available, the Dako Herceptest for immunohistochemical assay is considered the most reliable to reach this goal. The aim of this study was to investigate within a group of Italian laboratories the reproducibility of the results of HER-2/neu assessment by means of the Dako scoring system on slides stained with the Herceptest kit. This study was also conceived as the continuation of one of our previous studies, which was similar in its aims but different in the classification criteria adopted. Our results show that, whereas the intra-observer reproducibility was generally satisfactory, the interobserver reproducibility was not. Moreover, our findings confirm that the two extreme classes (0 and 3+) are more easy to identify than the other two and that the Herceptest does not allow to discriminate optimally between scoring classes 2+ and 3+. These findings are relevant in clinical practice where the treatment choice is based on categories defined by this assay, suggesting the need of adopting educational programs and/or new reference materials to improve the assay performance.

AB - The clinical interest in HER-2/neu is related to trastuzumab, a drug used to treat patients with invasive breast carcinoma overexpressing the HER-2/neu protein. It is very important to correctly identify those patients who may benefit from trastuzumab by accurate assessment of the HER-2/neu status. Of the various methods available, the Dako Herceptest for immunohistochemical assay is considered the most reliable to reach this goal. The aim of this study was to investigate within a group of Italian laboratories the reproducibility of the results of HER-2/neu assessment by means of the Dako scoring system on slides stained with the Herceptest kit. This study was also conceived as the continuation of one of our previous studies, which was similar in its aims but different in the classification criteria adopted. Our results show that, whereas the intra-observer reproducibility was generally satisfactory, the interobserver reproducibility was not. Moreover, our findings confirm that the two extreme classes (0 and 3+) are more easy to identify than the other two and that the Herceptest does not allow to discriminate optimally between scoring classes 2+ and 3+. These findings are relevant in clinical practice where the treatment choice is based on categories defined by this assay, suggesting the need of adopting educational programs and/or new reference materials to improve the assay performance.

KW - Breast cancer

KW - Herceptest

KW - Immunohistochemical HER-2/neu assessment

KW - Intra/Interoberver reproducibility

KW - Quality control

UR - http://www.scopus.com/inward/record.url?scp=27744522669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744522669&partnerID=8YFLogxK

M3 - Article

C2 - 16240847

AN - SCOPUS:27744522669

VL - 20

SP - 189

EP - 194

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 3

ER -